Cybersecurity firm ImmuniWeb has announced the opening of three new regional offices in London, Washington D.C. and Dubai. This expansion follows a record-breaking year in 2024 in which the company celebrated its fifth birthday with year-over-year sales growth while maintaining profitability.
The opening of the London office marks a significant milestone for ImmuniWeb and will serve as a hub for the company’s operations in the UK and Europe. The other offices will provide enhanced support and local presence for ImmuniWeb’s growing international customer base.
The company now serves over 1,000 enterprise clients in 50+ countries, delivering 24/7 support for its award-winning cybersecurity products and services. ImmuniWeb’s free Community Edition continues to provide essential security protection to universities, small businesses and municipal governments. With over 200,000 daily security scans, this initiative helps vulnerable organisations maintain essential security, privacy and compliance standards.
By establishing a physical presence in key regions, ImmuniWeb aims to strengthen its relationships with customers and partners, improve service delivery and comply with local regulations. The new offices in London, Washington D.C., and Dubai will enable the company to provide more localised support and expertise to its clients.
Dr. Ilia Kolochenko, Chief Architect & CEO at ImmuniWeb, commented: “We are delighted to announce new regional offices to further enhance our local presence in some of the most important regions to ensure state-of-the-art customer service and support round the clock. Demand for our services is rapidly growing, so do we. At ImmuniWeb, we are wholeheartedly grateful to every single customer and partner that we have: all of them contributed to our unstoppable international expansion, unsurpassed technical innovation and continuous year-over-year sales growth.” Kudos to the incredible ImmuniWeb Team, our success would have been impossible without your dedication, commitment and excellence.”
Image source: ImmuniWeb
